Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.51 |
| ▸ | ACE | P12821 | 5/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252365 | 1.00 | MME (0.51) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL31406596 | 0.93 | KISS1R (0.53) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL675899 | 0.92 | KISS1R (0.50) | ACENPY1RNPY2RNPY4ROPRD1 | |
| SCHEMBL675898 | 0.92 | KISS1R (0.50) | ACENPY1RNPY2RNPY4ROPRD1 | |
| SCHEMBL29738689 | 0.91 | BACE1 (0.55) | NPY1RNPY2RNPY4RBACE1KISS1R | |
| SCHEMBL29528212 | 0.91 | OPRD1 (0.57) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL30799540 | 0.91 | OPRD1 (0.54) | BACE1OPRD1OPRM1KISS1R | |
| SCHEMBL29657465 | 0.91 | BACE1 (0.56) | MMEACECPA1ACE2BACE1 | |
| SCHEMBL31721890 | 0.91 | PDCD1LG2 (0.53) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL30407854 | 0.90 | OPRD1 (0.57) | SLC6A2BACE1OPRD1OPRM1KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | MME 286/4885ACE 3899/4885CPA1 199/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | MME 286/4885ACE 3899/4885CPA1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.